HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- fluoro- 5- (5- (3- morpholin- 4- ylphenoxy)pyrimidin- 2- ylamino)benzonitrile

an amyloid-beta toxicity inhibitor; structure in first source

Also Known As:

SEN1500

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - 2-fluoro-5-(5-(3-morpholin-4-ylphenoxy)pyrimidin-2-ylamino)benzonitrile: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - 2-fluoro-5-(5-(3-morpholin-4-ylphenoxy)pyrimidin-2-ylamino)benzonitrile: 5

Experts

1.	Nerou, Edmund: 2 articles (12/2013 - 04/2013)
2.	Scopes, David I C: 2 articles (12/2013 - 04/2013)
3.	Treherne, J Mark: 2 articles (12/2013 - 04/2013)
4.	D'Apremont, Ivonne: 1 article (01/2021)
5.	Fabres, Jorge: 1 article (01/2021)
6.	Figueras-Aloy, Josep: 1 article (01/2021)
7.	García-Muñoz Rodrigo, Fermin: 1 article (01/2021)
8.	Mariani, Gonzalo: 1 article (01/2021)
9.	Musante, Gabriel: 1 article (01/2021)
10.	San Feliciano, Laura: 1 article (01/2021)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 04/01/2013 - "Behaviorally, oral administration of SEN1500 significantly reduced memory-related deficits in operant responding induced after intracerebroventricular injection of 7PA2 CM. SEN1500 reduced cytotoxicity, acute synaptotoxicity, and behavioral deterioration after in vitro and in vivo exposure to synthetic Aβ and 7PA2 CM, and shows promise for development as a clinically viable disease-modifying Alzheimer's disease treatment." 11/01/2017 - "SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease."
2.	Memory Disorders (Memory Loss) 11/01/2017 - "Memory deficits of APPSL mice could not be rescued by SEN1500. " 11/01/2017 - "SEN1500, an orally bioavailable and CNS-penetrant Aβ aggregation inhibitor, has previously been shown to reduce spatial learning and memory deficits in an APP transgenic mouse model. " 12/01/2013 - "Dose-dependent improvements in learning and memory deficits in APPPS1-21 transgenic mice treated with the orally active Aβ toxicity inhibitor SEN1500."
3.	Amyloid Plaque 11/01/2017 - "SEN1500 treatment lowered insoluble Aβ levels and β-amyloid plaque load in the brain compared with control-treated APPSL mice. "
4.	Enterocolitis 09/01/2020 - "Two questionnaires on the management of preterm infants less than 32 weeks, at risk of, or with diagnosed necrotising enterocolitis, were distributed among selected representatives of the surgeons and neonatologists of the Spanish Neonatal Network (SEN1500) participant hospitals with a Paediatric Surgery Department. "
5.	Birth Weight (Birth Weights) 01/01/2021 - "In addition to GA, birth weight, small for gestational age (SGA), female sex, and multiple gestation, less invasive resuscitation, and the network of origin were significant independent factors influencing survival (aHR [SEN1500 vs. NEOCOSUR]: 1.20 [95% CI: 1.15-1.26] and survival without major morbidity: 1.34 [95% CI: 1.26-1.43]). "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Amyloid (Amyloid Fibrils)

Related Therapies and Procedures

1.	Oral Administration
2.	Resuscitation